Arena Pharmaceuticals, Inc.

NASDAQ: ARNA
$75.83
+$2.14 (+2.9%)
Closing price September 28, 2020
Thursday's top analyst upgrades and downgrades included Costco, Enphase Energy, Etsy, Moderna, Novavax, Regeneron Pharmaceuticals, Roku, Square, Teva Pharmaceutical, Wayfair and Zynga.
Monday's top analyst upgrades and downgrades included Albermarle, Biogen, Dun & Bradstreet, eBay, First Solar, Lemonade, Morgan Stanley, Procter & Gamble, Schlumberger and Verizon Communications.
Monday's top analyst upgrades and downgrades included Amazon.com, Beyond Meat, Diamondback Energy, Enphase Energy, Groupon, Nuance Communications, PG&E, Spotify and ZoomInfo,
Monday's top analyst upgrades and downgrades included Apple, Best Buy, Cinemark, Co-Diagnostics, DraftKings, Energizer, Novavax, Nvidia, Palo Alto Networks and Petrobras.
Tuesday's top analyst upgrades and downgrades included Apache, Broadcom, Caterpillar, Dollar General, Microsoft, NXP Semiconductors, Salesforce.com, Sirius XM, Slack and Yelp.
Thursday's top analyst upgrades and downgrades included Alibaba, Apple, AT&T, Baidu, Chevron, Cisco Systems, Expedia, Goldman Sachs, Kroger, Micron Technology, Nike, Procter & Gamble, Square and...
Here are Credit Suisse's most recently added #1 Top Picks for 2020, including Honeywell and Micron Technology.
The top analyst upgrades, downgrades and initiations seen on Thursday included Arena Pharmaceuticals, Autodesk, Coca-Cola, General Electric, Marvell, Monster Beverages, Nabors and Procter &...
Arena Pharmaceuticals shares jumped early on Thursday after the company announced a new global license agreement with United Therapeutics.
The top analyst upgrades, downgrades and other research calls from Thursday include Biogen, Box, Corning, GrubHub, Hyatt, Quality Systems and Zillow.
Arena Pharmaceuticals shares climbed early on Tuesday after the firm announced positive midstage results from its Phase 2 trial for etrasimod.
The top analyst upgrades, downgrades and other research calls from Tuesday include AK Steel, BHP Billiton, Dominion Energy, JB Hunt, KLA-Tencor, Micron Technology, Nucor, Oracle, Roku and U.S. Steel.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Credit Suisse sees tax reform sparking a wave of mergers in the emerging pharmaceuticals space, which could produce sector outperformance. The firm is cautiously optimistic on this front.
The top analyst upgrades, downgrades and other research calls from Wednesday include Bank of America, Honeywell, IBM, Lululemon Athletica, Oracle, United Technologies and Wells Fargo.